Bioengineering Technologies for Cardiac Regenerative Medicine

Mira Chingale1, Dashuai Zhu1,2, Ke Cheng1,2* and Ke Huang1,2*

1 Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, United States, 2 Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, North Carolina State University, Raleigh, NC, United States

Cardiac regenerative medicine faces big challenges such as a lack of adult cardiac stem cells, low turnover of mature cardiomyocytes, and difficulty in therapeutic delivery to the injured heart. The interaction of bioengineering and cardiac regenerative medicine offers innovative solutions to this field. For example, cell reprogramming technology has been applied by both direct and indirect routes to generate patient-specific cardiomyocytes. Various viral and non-viral vectors have been utilized for gene editing to intervene gene expression patterns during the cardiac remodeling process. Cell-derived protein factors, exosomes, and miRNAs have been isolated and delivered through engineered particles to overcome many innate limitations of live cell therapy. Protein decoration, antibody modification, and platelet membranes have been used for targeting and precision medicine. Cardiac patches have been used for transferring therapeutics with better retention and integration. Other technologies such as 3D printing and 3D culture have been used to create replaceable cardiac tissue. In this review, we discuss recent advancements in bioengineering and biotechnologies for cardiac regenerative medicine.

Keywords: bioengineering, cardiac repair, cell reprogramming, exosome, cardiac patch, targeting

INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of death in both developed and developing countries. According to the World Health Organization (WHO), 17.9 million people across the globe (31%) die due to CVD, of which 85% die from myocardial infarction (MI) (World Health Organization, 2021). In adult hearts post-MI, injured heart muscle cells are replaced by fibrotic tissue. During this maladaptive remodeling process, activated cardiac fibroblasts turn into myofibroblasts, causing stiffness and fibrosis, which is, in turn, associated with poor prognosis and heart failure. Though cardiac fibroblasts provide structural integrity to the heart after MI, it also causes a non-contracting scar. Such events hamper cardiac perfusion and pumping capacity and leads to cardiac remodeling further toward deprivation to cardiac dysfunction, myocardium loss, and, eventually, heart failure (Xin et al., 2013; Saparov et al., 2017; Tallquist and Molkentin, 2017; Bo et al., 2020; Nelson and Brunt, 2021).

Conventional treatments for MI include coronary artery bypass, coronary reperfusion therapy, and fibrinolytic therapy, which are mainly for acute symptom relief rather than to promote repair and regeneration of the damaged myocardium (Awada et al., 2015). A heart transplant or a left ventricular assist device (LVAD) (Rose et al., 2001) is the final treatment option for heart failure patients. However, prognosis varies due to the complexity of the required highly invasive transplant surgery and its subsequent acute/chronic immune rejections (White and Chew, 2008;
Wilm, 2015). Although pharmacological treatments of β-blockers and angiotensin-converting enzyme (ACE) inhibitors (Packer et al., 2001; McMurray et al., 2014) are beneficial to MI patients, these existing approaches make it necessary to explore new methods of treatment that aim at regenerating the infarcted myocardium as well as becoming implementable in the clinical practices (Raziyeva et al., 2020).

Biomedical engineering seeks to close the gap between engineering and medicine by combining the design and problem-solving skills of engineering with medical and biological sciences. Biomedical engineering hopes to advance health care treatment, including diagnosis, monitoring, and therapy. It has been transforming the cardiac regenerative approaches into potential treatments for CVD (Lee and Walsh, 2016). Treatments for ischemic/reperfusion-damaged or infarcted myocardium have been designed by using multifarious biotechnologies based on the purpose of treatment. With the idea of using autologous cells for cardiac treatment, patient-specific cardiomyocytes (CMs) were generated through cell reprogramming technologies (Wang et al., 2021). To improve the regenerative capability of CMs, various viral and non-viral vectors have been used for gene editing to intervene with gene expression during cardiac remodeling process after MI (Rincon et al., 2015; Kohama et al., 2020). To overcome the retention, fragile, tumorigenicity, and immunogenicity limitations of cell therapy (Tang et al., 2018c), cell-derived protein factors, exosomes, and miRNAs have been isolated and delivered through micro- (Huang et al., 2020) or nanosized particles (Su et al., 2018b). For better targeting, scientists have used proteins, antibodies, and platelet membranes to decorate their therapeutics. For better retention and integration, cardiac patches have been designed by transfer therapeutics in vehicles made of various biomaterials (Mei and Cheng, 2020). Additionally, 3D printing (Maiullari et al., 2018) and 3D culture (Jackman et al., 2018) technologies were utilized to create replaceable cardiac tissue (Figure 1 and Table 1). In this review, we will discuss current biotechnologies for cardiac repair.

CELL REPROGRAMMING

Cell reprogramming is a powerful tool that converts the somatic cell lineage into pluripotent stem cells (iPSCs) (Rao and Malik, 2012), CMs (Fu et al., 2015) or endothelial cells (ECs) (Lee C. S. et al., 2017). Generally, this tool is used both in vitro and in vivo for cardiac injury site repair (Patel et al., 2016), cardiac disease modeling, or drug screening (Ebert et al., 2012; Chen and Vunjak-Novakovic, 2018). In the process of changing cell fate, an intermediary pluripotent state is key to differentiate direct and indirect reprogramming (Wang et al., 2021).

Indirect Cell Reprogramming

Indirect cell reprogramming from adult somatic cells to iPSC-derived CMs (iPSC-CMs) is a well-established process (Tai et al., 2018). iPSCs from multiple origins are now commercially available. This reprogramming method is widely used not only due to the difficulty of culturing human primary CMs in vitro but also because they contain patient-specific genomic information and could be used for autologous cardiac regenerative medicine (Martins et al., 2014). Commonly, adult fibroblasts are reprogrammed into iPSCs through the activation of alkaline phosphatase, silencing of somatic-specific expression, expression of SSEA1, and progressive silencing of exogenous genes with upregulation of Oct4 and Nanog (Teshigawara et al., 2017). However, these CMs are closer to an immature stage in terms of marker expression, ultrastructural features, metabolic signature, and electrophysiological properties (Tang, 2020). First, the origin of somatic cells is a determinant of iPSC-CM maturation (Pianezzi et al., 2020). Comparison of iPSC-CMs derived from cardiac-derived mesenchymal progenitor cells (CPCs), bone marrow-derived mesenchymal stem cells (BMSCs), and human dermal fibroblasts (HDFs) that comes from the same patient showed the cardiac somatic cell’s enhanced capacity for cardiac re-differentiation due to upregulated cardiac genes (MYH6, TNNI3, KCNQ1, KCNE1) (Altomare et al., 2016; Pianezzi et al., 2020). Additionally, the application of iPSC-CMs is highly affected by the purification process because tumors can form during in vitro culture of iPSCs that increase the malignant risks to in vivo application (Tohyama et al., 2013). To overcome the purification obstacles, a distinct metabolic flow technology has been designed to enable large-scale purification through glucose depletion and lactate supplementation because the mature iPSC-CMs have a higher oxygen consumption rate with increased mitochondrial maturity (Tohyama et al., 2013; Tang, 2020).

Direct Cell Reprogramming

Direct cell reprogramming is a process of transforming of somatic cells to a desired cell fate without a pluripotent or multipotent state (Wang et al., 2021). Ideally, direct cell reprogramming is more suitable for in vivo cardiac tissue repair by generating reprogrammed cells in situ in the diseased heart (Wang et al., 2021); however, it is still challenging to perform it in vivo due to the low transforming efficiency. For example, direct reprogramming of transcriptional factors like Gata4, Oct4, Tbx5, Sox2, and Klf4 were delivered directly into the damaged heart to initiate regeneration (Ieda et al., 2010; Chen et al., 2017; Hashimoto et al., 2018). Six core transcriptional factors Gata4, Hand2, Mef2c, Mesp1, Nkx2.5, and Tbx5 were examined for their cardiac lineage reprogramming capability (Li et al., 2015; Wang et al., 2015). Retroviruses were used to express these transcription factors in fibroblasts that were derived from adult mice (Pasumarthi and Field, 2002; Ieda et al., 2010; Song et al., 2012). Another study reported in vitro formation of CMs from fibroblasts by expressing transcriptional factors Gata4, Mef2c, and Tbx5 (GMT) and thereby functionally repopulating the scar (Qian et al., 2012; Wang et al., 2015). Although direct cell reprogramming bypasses early developmental stages (Barreto et al., 2019) such as the cardiac progenitor stages, the tumorigenic risks may not lower than indirect reprogramming because the small molecules cannot be guaranteed, which can also produce iPSCs (Chen et al., 2017). Most importantly, the fate of transduced cells in vivo is still debated, although single-cell transcriptomics have been done to discover the mechanism of the fate conversion from fibroblast to CMs.
Additionally, miRNAs have the ability to regulate various signaling pathways at the same time, which makes them a promising alternative (Sandmaier and Telugu, 2015). Researchers provided evidence that direct administration of miRNAs through lipid-based transfection at the target site successfully converted fibroblasts into cardiomyocytes in vivo (Elmén et al., 2008; Sridharan and Plath, 2011). Cardiac reprogramming through miRNAs (miR-1, miR-133, miR208, and miR499) was enhanced when combined with JAK inhibitor I treatment (Jayawardena et al., 2012).

**GENE EDITING**

Many genes are essential for CM proliferation and cardiac repair. For example, ERBB2 has been reported triggering mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation through YAP activation and EMT (epithelial–mesenchymal transition)-like processes (D’Uva et al., 2015; Aharonov et al., 2020). Cyclin A2 or CCNA2, a gene normally silenced after birth, has been demonstrated as a key cell cycle regulatory gene to induce cardiac repair by mediating both the G1–S and G2–M transitions of the cell cycle (Shapiro et al., 2014). So, an efficient delivery of the desired gene to heart is important for cardiac gene therapy.

**Non-viral Gene Delivery**

In cardiac gene therapy, efficient delivery of the desired gene to target tissue is important. Non-viral gene delivery methods, such as needle or jet injection, hydrodynamic gene transfer, electroporation, and cationic lipids make use of natural or synthetic compounds or physical forces to deliver the gene of interest to the target site. It is an important technology for tissue engineering with many features, including low toxicity, easy modification, high productivity, and cell specificity (Wu et al., 2018). A needleless liquid jet methodology using a jet device with micro jets has been used to expand or generate cell pores for cardiac gene delivery. However, it is not suitable for cardiac applications due to the jet’s piercing with high force (Fargnoli et al., 2017). Additionally, hydrophilic naked DNA could be consumed by cells (Al-Dosari and Gao, 2009); however, only a small percentage of target cells express the delivered genes, thus, making them inefficient.

**Viral Gene Delivery**

Recombinant viral vectors such as adenoviruses, lentiviruses, and adeno-associated viruses are generally used for gene delivery (Wolfram and Donahue, 2013). Adenoviral gene delivery systems have been extensively used in gene-based therapies and cell-based therapies. Adenoviral vectors have shown a
TABLE 1 | Summarization of advantages and disadvantages in different bioengineering methods.

| Bioengineered methods               | Advantages                                      | Disadvantages                        |
|-------------------------------------|-------------------------------------------------|--------------------------------------|
| Direct cell reprogramming           | • Needs no iPSC stage                           | • Low efficiency                     |
|                                     | • Possibility for in situ reprogramming         | • Unclear cell fate stability        |
|                                     | • Relatively rapid conversion                   | • Tumorigenicity risks               |
| Indirect cell reprogramming         | • High efficiency                               | • Requires iPSC stage                |
|                                     | • iPSC induction from many cell types           | • Only can be performed in vitro     |
|                                     | • Self-renewal of iPSCs                         | • The CMs are not mature             |
|                                     | • Differentiation condition is modulable        | • Tumorigenicity risks               |
|                                     | • Cell fate stability                           |                                      |
|                                     | • Suitable for ex vivo manipulations            |                                      |
| Non-viral gene delivery             | • Non-pathogenic                                | • Low transduction efficiency        |
|                                     | • Multiple delivery methods, e.g., Naked DNA    | • Cytotoxicity                       |
|                                     | • Direct delivery, gene gun, electroporation,   | • Transient transfection             |
|                                     | • ultrasound, lipopolyplexes and polyplexes etc.| • Tissue damage                      |
|                                     | • Simplicity in manufacturing                   | • Shallow penetration                |
|                                     | • Flexibility in packaging capacity             | • Immunogenicity                     |
| Viral gene delivery                 | • High transduction efficiency                  | • Difficult to produce high viral    |
|                                     | • Transient or persistent expression            | titers                              |
|                                     | • Multiple viral vector choices                 | • Immunogenicity                     |
|                                     |                                                  | • Limitations in gene packaging      |
| Synthetics particles                | • High biocompatibility                         | • Safety issues                      |
|                                     | • Cryo-stability                                | • Expensive                          |
|                                     | • Easy manipulation of particle contents        |                                      |
|                                     | • Cardiovascular targeting can be achieved      |                                      |
|                                     | • Degradable                                    |                                      |
|                                     | • Multiple delivery routes                      |                                      |
|                                     | • Controlled release of therapeutics            |                                      |
| Natural particles (extracellular    | • High biocompatibility                         | • Quality depending on cell batches  |
| and exosomes)                       | • Low immunogenicity                            | • and culture condition              |
|                                     | • Low tumorigenicity                            | • Variation in batches               |
|                                     | • Long term stability                           | • Low yield and purity               |
| Non-cellular cardiac patches        | • Multiple biomaterial selections               | • Difficulty in isolation            |
|                                     | • High biocompatibility                         |                                      |
|                                     | • Easy manufacturing and off-the-shelf          | • Hard to transplant in vivo         |
|                                     | • Suitable for large amount of cargo delivery   | • Low cardiac integration            |
|                                     | • Easy storage and transfer                     | • Low cardiac penetration            |
| Cell cardiac patches                | • Highly biocompatible                          | • Tumorigenicity                     |
|                                     | • Highly functional                             | • The maturation of CMs in tissue    |
|                                     | • Suitable for both in vivo and in vitro studies| • patch                              |
|                                     | • Multiple designs                              | • Hard to manufacture                |
|                                     |                                                  | • Batch-to-batch variation (depending  |
|                                     |                                                  | • on cell quality)                   |
|                                     |                                                  | • Very fragile and hard to transfer  |
|                                     |                                                  | • and storage                        |
|                                     |                                                  | • Low vascularization after          |
|                                     |                                                  | transplantation                      |

High transduction rate in both dividing and non-dividing cells (Lee S. et al., 2017). The knockdown of lncRNA through adenovirus-mediated lncRNA approaches lead to the reduction in macrophage infiltration and cardiomyocyte apoptosis in the heart after MI (Wang K. et al., 2017). Although adenovirus vectors were used in clinical trials due to their large tropism profile (Jessup et al., 2011), adenoviral-mediated gene delivery triggers immunogenicity in humans and lacks integration with the host genome, making it an unfavorable choice (Vilaysane and Muruve, 2009; Wasala et al., 2011). Lentiviral vectors are suitable for long-term transgene expression, which integrates their genome into the hosts with a preference for transcriptionally active sites (Bulcha et al., 2021). Lentiviral vectors can also elicit relatively weak immune responses through vector design (Bulcha et al., 2021). Lentiviral-mediated CCND2 gene transfection enhanced the regenerative potency of iPSCs-CMs (Zhu et al., 2018). Additionally, enhanced expression of Gata-4 and Nkx2.5 by lentiviral-mediated prodynorphin vectors resulted in a drastic increase in the CMs' beating activity (Rincon et al., 2015). However, lentiviral vectors are limiting for cardiovascular disease treatments due to their low transduction rate in the myocardium in vivo (Rincon et al., 2015). The adeno-associated virus (AVV), as a cardiotropic vector, can be designed as a viral therapeutic to promote cardiac repair after MI (Yoo et al., 2018). AAV6 was reported as the most effective vector to transduce CMs (Ambrosi et al., 2019). For example, AAV6 was designed
to deliver miR-199a to a pig model of MI (Gabisonia et al., 2019). Although the results showed cardiac improvement after 1 month, all pigs died due to subsequent uncontrolled expression of miR-199a that resulted in sudden arrhythmia.

**PARTICLE DESIGN**

Stem cell therapy has been a promising approach mediated through paracrine effects (Maghin et al., 2020; Sid-Ottmane et al., 2020). However, engraftment of transplanted cells and their low retention limit its therapeutic efficacy. Also, other concerns such as tumorigenicity, immunogenicity, and product stability need to be taken into account (Tang et al., 2018c). Since stem cells secrete a plethora of molecules like cytokines, soluble proteins, and extracellular vesicles that help in cardiac repair and regeneration (Tao et al., 2018), analysis of the cell secretome has gained importance in elucidating therapeutic mechanisms (Ellison-Hughes and Madeddu, 2017).

**Synthetic Particles**

Micro-sized synthetic stem cells (SSCs) have been fabricated to mimic the paracrine effects of a live cell through a cell-mimicking microparticle (CMMP) technology (Tang et al., 2017; Huang et al., 2020). Briefly, poly lactic-co-glycolic acid (PLGA) is used to encapsulate the stem cell-derived secretomes. Afterward, microparticles are coated with cell membranes to become SSCs (Tang et al., 2017). This technology not only overcomes the multiple inherent limitations of live-cell therapy (Huang et al., 2020) but also holds a high applicability for different cell lines, for example, both cardiac stromal cells (CSCs) and mesenchymal stem cells (MSCs) have been synthetically created (Luo et al., 2017; Tang et al., 2017; Huang et al., 2020). Additionally, to transfer miR21 into macrophages and ECs, positively charged mesoporous silica nanoparticles (MSNs) are designed to encapsulate miR21 and are injected into the ischemic heart of pigs for treatment (Li Y. et al., 2021). MSNs are reported as a highly biocompatible and transfection-effective nanoparticle that is generated through a classical CTAB-templated, base-catalyzed sol–gel method (Li Y. et al., 2021). These microparticles exert their beneficial effects mainly through mimicking cell paracrine of protein factors and membrane-based cell–cell interaction with injured cells (Luo et al., 2017; Tang et al., 2017). Also, the nanoparticles that are consumed by CMs and fibroblasts release the enclosed miRNAs and proteins to regulate gene expression (Hodgkinson et al., 2015). To fully understand the mechanism, the combination of cell secretomes have to be further studied because the cardiac beneficial results may come from the combination or any of the secretome contents, including miRNAs, protein factors, exosomes, extracellular vesicles, and so on. Moreover, cell secretome is not standardized due to the variation of cell lines, culture conditions, and purity, which makes it even harder to uncover the veil of cell therapy.

**Natural Particles**

Exosomes, a type of EVs, are bilipid layered nanovesicles with a diameter of around 35–150 nm that carry encapsulated proteins, membrane-bound proteins, and miRNAs and are capable of triggering various complex function-altering pathways (Li et al., 2017; Sun et al., 2018). Their small size allows them to pass through small capillaries, giving them more access to tissues than transplanted cells (Verweij et al., 2019; Dinh et al., 2020). Exosomes can be extracted and purified through techniques such as immunoaffinity capture, polymeric precipitation, tangential flow ultracentrifugation and size exclusion. Exosomes isolated from several cell lines including MSCs (Huang P. et al., 2019; Hu et al., 2021), iPSCs (Gao et al., 2020), cardiosphere-derived cells (CDCs) (Vandergriff et al., 2015; Gallet et al., 2017), and CPCs (Barile et al., 2017) have demonstrated cardiac protection through neovascularization and anti-inflammation (Teng et al., 2015; Huang P. et al., 2019). MSC-derived exosomes also contain miRNAs (miR-30b, let-7f, miR-424, and miR-30c) that promote angiogenesis. For example, MSC-derived exosomal miR-21-5p heightens cardiac contractile strength and calcium handling through PI3K signaling (Mayourian et al., 2018; Qiao et al., 2019).

**CARDIAC TARGETING**

Heart stem cell therapy is usually administered intramyocardially via open-chest or percutaneous coronary intervention (PCI) (Malliaras and Marbán, 2011). As the invasive nature of this drug delivery is not effective and appealing, researchers focus on developing therapeutics with targeting ability to the injured myocardium. This concept allows drugs to interact specifically with the injured and impart therapeutic benefits. Various targeting strategies, such as cardiotropic vector selection, peptide decoration, magnetic reactive carrier, or antibody editing have been employed for efficient drug delivery (Cores et al., 2015; Weinberger and Eschenhagen, 2021).

**Cardiotropic Vector Selection**

Cardiac gene therapy requires viral vectors to safely access the heart specifically. So, it is essential to find a cardiotropic vector for gene delivery. For example, although multiple strains of AAVs from serotypes 1 to 9 have been isolated, only AAV9 (Inagaki et al., 2006) and AAV6 (Bish et al., 2008; Gao et al., 2011) showed a higher transduction efficiency. However, these vectors require intrapericardial or intramyocardial administration. Since there is a difference in host specificity (Asokan and Samulski, 2013), it is even harder to evaluate AAV vectors in preclinical models and clinical translation.

**Peptide Targeting**

Peptide-based targeting has been achieved by decorating peptide (Kanki et al., 2011) onto therapeutics. A 12-amino acid non-naturally occurring peptide NH2-APWHLSSQYSRT-COOH was reported as a cardiomyoct-e targeting peptide (Feldman and Zahid, 2020). The peptide motif CSTSMLKAC was also identified as a potential tool for heart homing (Sherke et al., 2008; Kanki et al., 2011). For example, CDC-derived exosomes were designed to target the heart injury site via cardiac homing peptide CSTSMLKAC through a dioleoylphosphatidylethanolamine N-hydroxysuccinimide (DOPE-NHS) linker on the exosomal
membrane (Shelke et al., 2008). Since the prostaglandin E2 (PGE2) receptors are overexpressed in the pathological cardiac microenvironment after ischemic/reperfusion injury (Kim et al., 2008; Zhang et al., 2015), researchers decorated PGE2 on nanoparticles through EDC/NHS coupling chemistry to increase cardiac homing capability (Su et al., 2018b).

**Platelet Targeting**
Platelet-based targeting has been designed based on the inherent properties of platelets. Platelet surface receptors such as the GPIb/IX/V complex, GPVI and αβ integrins, are responsible for interactions with exposed injury sites (Li et al., 2018). The platelet membrane has been isolated and coated on either cell (Shen et al., 2016; Tang et al., 2018a), micro- (Li et al., 2020) or nano- (Su et al., 2018b) particles to endow cardiac injury site homing capability (Li et al., 2018). To increase targeting and cellular uptake of nanoparticles on coronary artery stents, scientists activated ECs through binding P-selectin to platelet glycoprotein Ibα (GP Ibα) on platelet-mimicking nanoparticles (Lin et al., 2010).

**Antibody Targeting**
There are many cardiac targeting approaches designed to utilize the innate specific binding capability of antibodies. Bispecific antibodies (BsAbs) have been designed to bind two different targets simultaneously by combining variable domains of desired monoclonal antibodies into an integrated structure (Huang et al., 2019a). BsAbs are generated by chemical conjugation, hybridoma fusion, or genetic engineering such as recombinant DNA technology (Parashar et al., 2011). To redirect endogenous bone marrow stem cells (BMSCs) to the injured heart, BsAbs were designed to link F(ab′)2 fragments from monoclonal anti-CD34 and anti-cardiac myosin heavy chain through chemical cyclododition of AZ-PEG-NHS or DBCO-PEG-NHS on those F(ab′)2 fragments (Huang et al., 2019b). In this study, after G-CSF stimulation, the administration of BsAbs redirected circulating BMSCs to the injured myocardium (Huang et al., 2019b). Additionally, an inhalable platelet-targeting bspecific antibody (PT-BsAb) was designed by linking of CD34 (HSC binding) and CD42b (platelet binding) to redirect stem cells from the lungs to the heart for repair (Liu M. et al., 2021).

To increase the targeting capability of the injury site, a poly (N-isopropylacrylamide) nanogel with tissue plasminogen activator (tPA) and cell contractility inhibitor Y-27632 coupled anti-fibrin antibodies on the outside of nanoparticles through an EDC/sulfo-NHA method (Mihalko et al., 2018). The injected nanoparticles were directed by anti-fibrin antibodies to the fibrin-rich site post-MI and released tPA and Y-27632 to the site of injury (Mihalko et al., 2018; Huang et al., 2019b). Besides targeting, antibodies were also decorated on platelet-inspired cardiac-targeting microparticles to neutralize inflammatory cytokines. For example, since IL-1β has been demonstrated as a primary pro-inflammatory cytokine during cardiac remodeling, IL-1β antibodies were linked to platelet membrane on microparticles through 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly (ethylene glycol) (DSPE-PEG) (Li et al., 2020).

**CARDIAC PATCH DESIGN**
Cardiac patches have been devised to ameliorate the cardiac function post-MI (Mei and Cheng, 2020). A cardiac patch is typically composed of substrate and active therapeutic agents (Yang et al., 2013). Cardiac patches can have therapeutic ingredients ranging from cells, such as iPSCs, myoblasts and MSCs, to bioactive molecules, such as miRNAs, exosomes, and microparticles (Mei et al., 2010; Squillaro et al., 2016; Wang L. L. et al., 2017; Giacomelli et al., 2020).

**Cellular to Non-cellular Patches**
Cell-based cardiac patches have been designed to increase the survival ratio of the embedded cells and to ensure cellular retention (Braunwald, 2018; Zhu et al., 2021). For example, a recently developed cardiac patch fabricated with biomimetic microvessels and CSCs in fibrin gel enhanced angiogenesis, CSC retention, and survival rate after heart transplantation (Gao et al., 2018; Su et al., 2018a). Furthermore, non-cardiac cellular patches have been designed to overcome the limitations of live cellular cardiac patches (Tang et al., 2018b; Li Z. et al., 2021). For example, a specific miRNA patch was designed to modulate gene expression during cardiac remodeling (Wang L. L. et al., 2017). For miR-302 cardiac delivery, researchers designed a system by using a cholesterol molecule to decorate miR-302 mimics and using adamantane or cyclodextrin to modify hydrogels. Since the modified hydrogel showed self-assembly into shear-thinning and self-healing gels, the cholesterol on miR-302 mimics interacts with cyclodextrin to achieve sustained release (Wang L. L. et al., 2017; Huang et al., 2019a). To enhance clinical feasibility, an off-the-shelf cardiac patch was designed by embedding synthetic cardiac stromal cells into a decellularized extracellular matrix through a vacuum filtration method (Huang et al., 2020). In addition, exosomes derived from MSCs were integrated into hydrogels, providing a minimally invasive delivery method through intrapericardial injection. This injectable patch revolutionized the delivery of cardiac patches, which normally needs a traumatic open-chest surgery (Zhu and Cheng, 2021; Zhu et al., 2021).

**Tissue Patches**
Cardiac tissue patch is one important type of cell-based patches that has been created by culture of embryonic stem cell-derived cardiomyocytes (ESC-CMs) (Chong et al., 2014), iPSC-CMs, or neonatal rodent cardiomyocytes (NRCMs) into a 3D scaffold to form a functional 3D structure (Pomeroy et al., 2020). For example, cardiac tissue patches cultured with multiple layers of iPSC-CMs or NRCMs within hydrogels or other porous polymer scaffolds form a randomly oriented and electromechanically integrated cardiac tissue patch (Shadrin et al., 2017; Pomeroy et al., 2020). In a window chamber model and a rodent MI model, the iPSC-CM 3D cardiac patch showed a preserved structure, electrical function, and successful vascularization (Shadrin et al., 2017; Cui et al., 2020). Implantation of this engineered cardiac tissue patch to the injured heart in vivo showed improved vascularization in the infarct region and reduced fibrosis (Wendel...
The goal of gene therapy for cardiac repair is to modify a gene or genetic pathway. Safety and efficacy are important to develop tolerance and ease administration that may be translated to the clinic (Wolfram and Donahue, 2013). For example, adenoviral vectors may trigger acute inflammation, which impacts gene transfer efficacy and may cause host morbidity (Liu and Muruve, 2003). Also, gene delivery through the myocardium or coronary injections has a low cardiac transfection outcome due to the neutralization by existing endogenous antibodies (Jessup et al., 2011). As previously mentioned, long-term expression of target genes may also cause sudden death in pig studies (Gabisonia et al., 2019).

Different types of stem cells have been studied as potential candidates for cardiac regenerative medicine. However, live stem cell delivery has many inherent limitations such as tumorigenicity, immunogenicity, cell death, and low retention after transplantation (Tang et al., 2018c). So, multiple cell-derived secretomes, exosomes, and miRNAs have been engineered as alternatives for heart repair by mimicking paracrine effects of the cell or manipulating gene expression during cardiac remodeling after MI. These cell-derived therapeutics have been combined with different biomaterials to overcome the limitations of low cardiac engraftment/retention, low miRNA stability, and delivery difficulties (Huang et al., 2019a).

Non-targeted cardiac therapeutics with an intravenous delivery usually affects multiple systems, which may cause systemic side effects. Targeted therapeutics, on the other hand, are designed for precise cardiac treatment with one or multiple intravenous injections. The targeting technology is achieved mainly through decorating a cardiac homing molecule on nanosized particles, which are safe in circulation with minimal chance of stimulating coagulations (Dobrovolskaia et al., 2009). Additionally, endogenous stem cells may be stimulated and redirected by BsAbs (Huang et al., 2019b; Liu M. et al., 2021). However, all targeting methods have to be further studied due to the low targeting capability and treatment efficacy.

3D cardiac patches are a promising method in cardiac repair and are either cellular or non-cellular. The cellular patches are generated through seeding of different live cells into various 3D scaffolds. To enhance the survival of the transplanted live cells, the patches have been engineered with mimetic blood vessels (Su et al., 2018a, 2020) or cocultured with ECs (Shadrin et al., 2017). For better integration, the scaffold has been engineered with microneedles (Tang et al., 2018b). Additionally, researchers have manipulated cell growth and differentiation conditions through culture medium optimization to enhance the maturity of iPSC-CMs on tissue patches (Mačiraju and Greenway, 2019). Non-cellular patches are generated by seeding different cell derivatives into various 3D scaffolds. Compared with cellular cardiac patches, these patches have better stability, biocompatibility, modifiability, and low tumorigenicity and immunogenicity. 3D bioprinting technology has been widely utilized in cardiac repair by integrating biomaterials with different cell types to precisely pattern a cardiac structure (Liu N. et al., 2021). However, this technology is still in the early stage and needs to be improved (Liu N. et al., 2021).

CONCLUSION AND FUTURE DIRECTIONS

Cellular reprogramming is a new paradigm in cell biology and provides a unique and efficient way to generate cell types of interest for cardiac repair by changing one cell fate to another (Wang et al., 2021). Usually, the indirect reprogramming routes require an in vitro engineered 3D tissue and then transplant in vivo (Querdel et al., 2021). The direct reprogramming bypass early developmental stages and administer the cardiac transriptional factors directly by viral vectors. From a translational perspective, the technology of direct reprogramming holds great potential as a treatment due to its features including fast turnaround time and feasibility for in vivo applications (Wang et al., 2021). However, a large scale of somatic cells could be converted through indirect preprogramming to create a paradigm for in vitro CRISPR-Cas9 screening, drug screening, and disease modeling (Wang et al., 2021). Although cell reprogramming showed a potential strategy for the cardiac repair, there are few advantages and disadvantages in both reprogramming routes. Direct reprogramming rarely produces beating CMs after a long culture period (Fu et al., 2013; Nam et al., 2013). In comparison, indirect reprogramming is robust to produce beating CMs that are not in a mature stage. In addition, indirect reprogramming achieves a high conversion efficiency around 70 to even 90% (Pomeroy et al., 2020); however, direct reprogramming has a low conversion efficiency (4.8%) (Engel and Ardehali, 2018) due to the presence of epigenetic barriers such as Bmi1 (Zhou et al., 2016). This low conversion efficiency remains a major hurdle for direct reprogramming, and even the process was already improved by administering cardiac transcriptional factors along with epigenetic modifiers, inhibitors, cytokines, and miRNAs (Engel and Ardehali, 2018).
Additional biotechnologies not mentioned in this review such as cardiac spheroids, single ventricles, bundles, regenerative gene expression, and design of biomaterials also play an important role in the field. Although there are plenty of technologies, it is not easy to get past the bottleneck of heart regenerative medicine, for example, the maturity of iPSC-CMs, the optimized cell protein factor combination, the detailed miRNA regulation mechanism, the key gene for cardiomyocyte regeneration, creation of large-sized cardiac tissue (Gao et al., 2018), and control of drug delivery-caused trauma. To overcome these obstacles, future interdisciplinary cooperation will be the key in the research area. For example, engineering of an injectable material that have controlled gelation speed, biocompatibility, degradative ability, and temperature sensitivity will be essential to create an injectable cardiac patch. Also, screening and designing of cardiotropic viral vectors through structure evolution of capsid variants (Tse et al., 2017) would enhance cardiac gene therapy. Moreover, natural exosomes are not clinically feasible due to many inherent limitations that could be overcome through cell-based pre-isolation exosome engineering and post-isolation exosome engineering (Huang P. et al., 2019; Jafari et al., 2020). Although mainly practiced in research labs today, innovative experimental bioengineering technologies will revolutionize heart repair field in the future.

AUTHOR CONTRIBUTIONS

MC, DZ, and KH wrote the text of this review article with guidance from KC and KH. All authors have reviewed the final version and approved the content in this manuscript.

FUNDING

This work was supported by grants from the National Institutes of Health (R01 HL123920, HL137093, HL144002, HL146153, and HL147357 to KC) and the American Heart Association (18TPA34230092 and 19EIA34660286 to KC).

REFERENCES

Aharonov, A., Shakked, A., Umanovsky, K. B., Savidor, A., Gershulinakh, A., Kain, D., et al. (2020). ERBB2 drives YAP activation and EMT-like processes during cardiac regeneration. Nat. Cell Biol. 22, 1346–1356. doi: 10.1038/s41556-020-00588-4

Al-Dosari, M. S., and Gao, X. (2009). Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 11, 671–681.

Altmare, C., Pianezzi, E., Cervio, E., Bolis, S., Biemmi, V., Benzoni, P., et al. (2016). Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade. EuropACE 18(Suppl. 4), iv67–iv76.

Ambrosi, C. M., Sadananda, G., Han, J. L., and Entcheva, E. (2019). Adeno-associated virus mediated gene delivery: implications for scalable in vitro and in vivo cardiac optogenetic models. Front. Physiol. 10:68. doi: 10.3389/fphys.2019.00168

Asokan, A., and Samulski, R. J. (2013). An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum. Gene Ther. 24, 906–913. doi: 10.1089/hum.2013.2515

Awada, H. K., Hwang, M. P., and Wang, Y. (2015). Towards comprehensive cardiac repair and regeneration after myocardial infarction: aspects to consider and proteins to deliver. Biomaterials 82, 94–112. doi: 10.1016/j.biomaterials.2015.12.025

Barile, L., Mocchetti, T., Marbán, E., and Vassalli, G. (2017). Roles of exosomes in cardiac protection. Eur. Heart J. 38, 1372–1379.

Barreto, S., Hamel, L., Schiatti, T., Yang, Y., and George, V. (2019). Cardiac progenitor cells from stem cells: learning from genetics and biomaterials. Cells 8:1536. doi: 10.3390/cells8121536

Bish, L. T., Sleeper, M. M., Brainard, B., Cole, S., Russell, N., Withnall, E., et al. (2008). Percutaneous trans endocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in Canines. Mol. Ther. 16, 1953–1959. doi: 10.1038/mt.2008.202

Bo, B., Zhou, Y., Zheng, Q., Wang, G., Zhou, K., and Wei, J. (2020). The molecular mechanisms associated with aerobic exercise-induced cardiac regeneration. Biomolecules 11:19. doi: 10.3390/biom1100199

Braunwald, E. (2018). Cell-based therapy in cardiac regeneration: an overview. Circ. Res. 123, 132–137. doi: 10.1161/circressaha.118.313484

Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., Gao, G. (2021). Viral vector platforms within the gene therapy landscape. Signal Transduct. Target Ther. 6:53.

Chen, T., and Vunjak-Novakovic, G. (2018). In vitro models of ischemia-reperfusion injury. Regen. Eng. Transl. Med. 4 142–153.

Chen, Y., Yang, Z., Zhao, Z.-A., and Shen, Z. (2017). Direct reprogramming of fibroblasts into cardiomyocytes. Stem Cell Res. Ther. 8:118.

Chong, J. J. H., Yang, X., Don, C. W., Minami, E., Liu, Y.-W., Weyers, J. J., et al. (2014). Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510:273.

Cores, J., Caranasos, G. T., and Cheng, K. (2015). Magnetically targeted stem cell delivery for regenerative medicine. J. Funct. Biomater. 6, 526–546. doi: 10.3390/jfb6030526

Cui, H., Liu, C., Esworthy, T., Huang, Y., Yu, Z. X., Zhou, X., et al. (2020). 4D physiologically adaptable cardiac patch: a 4-month in vivo study for the treatment of myocardial infarction. Sci Adv. 6:eabb6507. doi: 10.1126/sciadv.abb6507

Cui, H., Miao, S., Esworthy, T., Zhou, X., Lee, S.-J., Liu, C., et al. (2018). 3D bioprinting for cardiovascular regeneration and pharmacology. Adv. Drug Deliv. Rev. 132, 252–269.

Cui, H., Nowicki, M., Fisher, J. P., and Zhang, L. G. (2017). 3D bioprinting for organ regeneration. Adv Healthc Mater. 6:10.1002/adhm.201601118 doi: 10.1002/adhm.201601118

Dinh, P. U. C., Paudel, D., Brochu, H., et al. (2020). Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 11:1084.

Dobrovolskaya, M. A., Patri, A. K., Zheng, J., Clogston, J. D., Ayub, N., Aggarwal, P., et al. (2009). Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 5, 106–117. doi: 10.1016/j.nano.2008.08.001

Duan, B. (2017). State-of-the-art review of 3D bioprinting for cardiovascular tissue engineering. Ann. Biomed. Eng. 45, 195–209. doi: 10.1007/s10439-016-1607-5

D’Uva, G., Aharonov, A., Lauriola, M., Kain, D., Yahalom-Ronen, Y., Carvalho, S., et al. (2015). ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 17, 627–638. doi: 10.1038/nclb3149

Dvir, T., Timko, B. P., Kohane, D. S., and Langer, R. (2011). Nanotechnological strategies for engineering complex tissues. Nat. Nanotechnol. 6, 13–22. doi: 10.1038/nnano.2010.246

Ebert, A. D., Liang, P., and Wu, J. C. (2012). Induced pluripotent stem cells as a main platform for cardiac regeneration. J. Cardiovasc. Pharmacol. 60, 408–416. doi: 10.1097/fjc.0b013e318247f642

Ellison-Hughes, G. M., and Madeddu, P. (2017). Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discovery. Pharmacol. Ther. 171, 1–12. doi: 10.1016/j.pharmthera.2016.11.007

Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899. doi: 10.1038/nature06783
Engel, J. L., and Ardehali, R. (2018). Direct cardiac reprogramming: progress and promise. Stem Cells Int. 2018:1435746.
Fargnoli, A. S., Katz, M. G., and Bridges, C. R. (2017). A needleless liquid jet injection delivery approach for cardiac gene therapy. Methods Mol. Biol. 1521, 219–229. doi: 10.1007/978-1-4939-6588-5_15
Feldman, K. S., and Zahid, M. (2020). In Vivo imaging of transduction efficiencies of cardiac targeting peptide. J. Vis. Exp. 11:160.
Fleischer, S., Feiner, R., and Dvir, T. (2017). Cutting-edge platforms in cardiac tissue engineering. Curr. Opin. Biotechnol. 47, 23–39. doi: 10.1016/j.copbio.2017.05.008
Fu, J.-D., Stone, N. R., Liu, L., Spencer, C. I., Qian, L., Hayashi, Y., et al. (2013). Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Rep. 1, 235–247. doi: 10.1002/stemcr.2013.07.005
Fu, Y., Huang, C., Xu, X., Gu, H., Ye, Y., Jiang, C., et al. (2015). Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails. Cell Res. 25, 1013–1024. doi: 10.1038/cr.2015.99
Gabisonia, K., Prosdociomo, G., Aquaro, G. D., Carlucci, L., Zentilin, L., Secco, I., et al. (2019). MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature 569, 418–422. doi: 10.1038/s41586-019-1191-6
Gallet, R., Dawkins, J., Valle, J., Simsolo, E., de Couto, G., Middleton, R., et al. (2017). Engineered cardiac valve. J. Mol. Cell Cardiol. 1126, 1465–1473. doi: 10.1016/j.yjmcc.2017.10.003
Hashimoto, H., Olson, E. N., and Bassel-Duby, R. (2018). Therapeutic approaches to myocardial infarction in swine. Sci. Transl. Med. 10, eaay0589.
Hu, S., Li, Z., Shen, D., Hui, Q., Bi, J., Yu, B., Huang, Z., et al. (2021). Injection of exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in pigs. J. Mol. Cell Cardiol. 50, 841–848. doi: 10.1016/j.yjmcc.2021.02.003
Kim, S. H., Jeong, J. H., Ou, M., Yokman, J. W., Kim, S. W., and Bull, D. A. (2008). Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polypelex formulated with reducible poly(aminodi amine) for preventing cardiomyocyte apoptosis. Biomaterials 29, 4439–4446. doi: 10.1016/j.biomaterials.2008.07.047
Kohama, Y., Higo, S., Masumura, Y., Shiba, M., Kondo, T., Ishizu, T., et al. (2020). Adeno-associated virus-mediated gene delivery promotes S-phase entry-independent precise targeted integration in cardiomyocytes. Sci. Rep. 10, 1–13.
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., et al. (2017). Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the near future of personalized medicine. Genes Dis. 4, 43–63. doi: 10.1016/gendis.2017.04.001
Lee, R. T., and Walsh, K. (2016). The future of cardiovascular regenerative medicine. Circulation 133, 2618–2625. doi: 10.1161/circulationaha.115.011133
Lee, S., Kim, J. E., Johnson, B., Al, Andukuri, A., and Yoon, Y.-S. (2017). Direct reprogramming into endothelial cells: a new source for vascular regeneration. Regen. Med. 12, 317–320. doi: 10.2217/rme-2017-0022
Li, P., Kaslan, M., Lee, S. H., Yao, J., and Gao, Z. (2017). Progress in exosome isolation techniques. Theranostics 7, 789–804. doi: 10.7150/thno.11133
Li, X.-H., Li, Q., Jiang, L., Deng, C., Liu, Z., Fu, Y., et al. (2015). Generation of functional human cardiac progenitor cells by high-efficiency protein transduction. Stem Cells Transl. Med. 4, 1415–1424. doi: 10.5966/scitm.2015-0136
Li, Y., Chen, X., Jin, R., Chen, L., Dang, M., Cao, H., et al. (2021). Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs. Sci. Adv. 7:eabd6740. doi: 10.1126/sciadv.abd6740
Li, Z., Hu, S., and Cheng, K. (2018). Platelets and their biomimetics for regenerative medicine and cancer therapies. J. Mater. Sci. Mater. Med. 6, 7354–7365. doi: 10.1039/c8bm02301h
Li, Z., Hu, S., Huang, K., Su, T., Cores, J., and Cheng, K. (2020). Targeted anti-IL-1β platelet microparticles for cardiac detoxifying and repair. Sci. Adv. 6:eaaa0589. doi: 10.1126/sciadv.aay0589
Li, Z., Zhu, D., Hui, Q., Bi, J., Yu, B., Huang, Z., et al. (2021). Injection of ROS-responsive hydrogel loaded with basic fibroblast growth factor into the pericardial cavity for heart repair. Adv. Funct. Mater. 2021:2004377. doi: 10.1002/adfm.202004377
Luo, L., Tang, J., Nishi, K., Yan, C., Dinh, P.-U., Cores, J., et al. (2017). Fabrication of endothelial-targeting nanoparticles. J. Biomed. Mater. Res. A 93, 833–842.

Liu, M., Lutz, H., Zhu, D., Huang, K., Li, Z., Dinh, P.-U., C., et al. (2021). Bispecific antibody inhalation therapy for redirecting stem cells from the lungs to repair heart injury. Adv. Sci. 8:2002127. doi: 10.1002/advs.20202127

Liu, N., Ye, X., Yao, B., Zhao, M., Wu, P., Liu, G., et al. (2021). Advances in 3D bioprinting technology for cardiac tissue engineering and regeneration. Bioact. Mater. 6, 1388–1401. doi: 10.1016/j.bioactmat.2020.10.021

Liu, Q., and Muruve, D. (2003). Molecular basis of the inflammatory response to adenosine receptors. Gene Ther. 10, 935–940. doi: 10.1038/sj.gt.3302036

Liu, Z., Wang, L., Welch, J. D., Ma, H., Zhou, Y., Vasighi, H. R., et al. (2017). Single-cell transcriptomics reconstructs fate conversion from fibroblast to cardiomyocyte. Nature 551, 100–104. doi: 10.1038/nature24454

Luo, L., Tang, J., Nishi, K., Yan, C., Dinh, P. U., Cores, J., et al. (2017). Fabrication of synthetic mesenchymal stem cells for the treatment of acute myocardial infarction in mice. Circ. Res. 120, 1768–1775. doi: 10.1161/circresaha.116.310374

Machiraju, P., and Greenway, S. C. (2019). Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes. World J. Stem Cells 11, 33–43. doi: 10.4252/wjsc.v11.i1.33

Maghini, E., Garbati, P., Quarto, R., Piccoli, M., and Bollini, S. (2020). Young at heart: combining strategies to rejuvenate endogenous mechanisms of cardiac repair. Front. Bioeng. Biotechnol. 8:447. doi: 10.3389/fbioe.2020.00447

Maiullari, F., Costantini, M., Milan, M., Pace, V., Chirivi, M., Maiullari, S., et al. (2018). A multi‐cellular 3D bioprinting approach for vascularized heart tissue engineering based on HUVECs and iPSC-derived cardiomyocytes. Sci. Rep. 8, 1–15.

Malliaras, K., and Marbán, E. (2011). Cardiac cell therapy: where we’ve been, where we are, and where we should be headed. J. Cell. Biochem. 113, 3061–3068. doi: 10.1002/jcb.21483

Raziev, K., Smagulova, A., Kim, Y., Smagul, S., Nurkeš, A., and Saparov, A. (2020). Preconditioned and genetically modified stem cells for myocardial infarction treatment. Int. J. Mol. Sci. 21:7301. doi: 10.3390/ijms2107301

Rincón, M. Y., VandenDriessche, T., and Chua, M. K. (2015). Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.Cardiovasc. Res. 108, 4–20. doi: 10.1093/cvr/cvtt003

Rao, M. S., and Malik, N. (2012). Assessing iPSC reprogramming methods for their suitability in translational medicine. J. Cell. Biochem. 113, 3061–3068. doi: 10.1002/jcb.21483

Sandmaier, S. E., and Telugu, B. P. (2015). MicroRNA-mediated reprogramming of somatic cells into induced pluripotent stem cells. Methods Mol. Biol. 1330, 29–36. doi: 10.1007/978-1-4939-2848-4_4

Saparov, A., Ogay, V., Nurgozhin, T., Chen, W. C. W., Mansurov, N., Issabekova, A., et al. (2017). Role of the immune system in cardiac tissue damage and repair following myocardial infarction. Inflamm. Res. 66, 739–751. doi: 10.1007/s00115-017-1060-4

Shadrin, I. Y., Allen, B. W., Qian, Y., Jackman, C. P., Carlson, A. L., Juhas, M. E., et al. (2017). Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat. Commun. 8:1825.

Shapiro, S. D., Banjan, A. K., Kawase, Y., Cheng, R. K., Kara, R. J., Bhattacharya, R., et al. (2014). Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes. Sci. Transl. Med. 6:224ra27. doi: 10.1126/scitranslmed.3006688

Shelke, A. R., Roscoe, J. A., Morrow, G. R., Colman, L. K., Banerjee, T. K., and Kirshner, J. J. (2008). Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community oncology program study. J. Pain Symptom Manage. 35, 381–387. doi: 10.1016/j.jpainsymman.2007.05.008

Shen, D., Tang, J., Hensley, M. T., Li, T., Caranasos, T. G., Zhang, T., et al. (2016). Effects of matrix metalloproteinases on the performance of platelet fibrin gel spiked with cardiac stem cells in heart repair. Stem Cells Transl. Med. 5, 793–803. doi: 10.5966/sctm.2015-0194

Shengjie, L., Xiong, Z., Wang, X., Yan, Y., Liu, H., and Zhang, R. (2009). Direct fabrication of a hybrid cell/hydrogel construct by a double-nozzle assembling technology. J. Bioact. Compat. Polym. 24, 249–265. doi: 10.1177/0883915091040949

Sid-Otmane, C., Perrault, L. P., and Ly, H. Q. (2020). Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes. J. Transl. Med. 18:336.

Song, K., Nam, Y. J., Luo, X., Qi, X., Tan, W., Huang, G. N., et al. (2012). Heart repair by reprogramming non-mycocytes with cardiac transcription factors. Nature 485, 599–603. doi: 10.1038/nature11139

Squillaro, T., Peluso, G., and Galderisi, U. (2016). Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 25, 829–848. doi: 10.3727/096368915x689622
Tao, S. C., Guo, S. C., and Zhang, C. Q. (2018). Modularized extracellular vesicles for targeted heart repair after ischemia/reperfusion injury. *Adv. Funct. Mater.* 0, 1803567. doi: 10.1002/adfm.201803567

Su, T., Huang, K., Mathews, K. G., Scharf, V. F., Hu, S., Li, Z., et al. (2020). Cardiac stromal cell patch integrated with engineered microvessels improves recovery from myocardial infarction in rats and pigs. *ACS Biomater. Sci. Eng.* 6, 6309–6320. doi: 10.1021/acsbiomaterials.0c00942

Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., et al. (2018). Effect of exosomal miRNA on cancer biology and clinical applications. *Mol. Cell. 17*, 1–19. doi: 10.1007/978-3-642-27841-9_7227-1

Tay, Y.-L., Chen, K.-C., Hsieh, J.-T., and Shen, T.-L. (2018). Exosomes in cancer development and clinical applications. *Cancer Sci.* 109, 2364–2374. doi: 10.1111/cas.13697

Tallquist, M. D., and Molkentin, J. D. (2017). Redefining the identity of cardiac progenitor cells. *Cell Stem Cell.* 12, 127–137. doi: 10.1016/j.stem.2016.10.006

Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., et al. (2017). Structure-guided evolution of antigenically distinct adeno-associated virus vectors. *Proc. Natl. Acad. Sci. U.S.A.* 114, E4812–E4821.

Uygun, B., Soto-Gutierrez, A., Yagi, H., et al. (2010). Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. *Nat. Med.* 16, 814–820. doi: 10.1038/nm.2170

Vandergriff, A. C., Andrade, J. B., Tang, J., Hensley, M. S., Piedrahita, J. A., Caranasos, T. G., et al. (2015). Intravenous cardiac stem-cell-derived exosomes ameliorate cardiac dysfunction in doxorubicin-induced cardiac dysfunction. *Stem Cells Int.* 2015, 969026.

Weverij, F. J., Revena, C., Arras, G., Dingli, F., Loew, D., Pegtel, D. M., et al. (2019). Live tracking of inter-organ communication by endogenous exosomes in vivo. *Dev. Cell.* 48, 573.e4–589.e4.

Vilayasane, A., and Muruve, D. A. (2009). The innate immune response to DNA. *Semin. Immunol.* 21, 208–214.

Wang, H., Yang, Y., Liu, J., et al. (2021). Direct cell reprogramming: approaches, mechanisms and progress. *Nat. Rev. Mol. Cell Biol.* [Epub ahead of print]. doi: 10.1038/s41580-021-00335-z

Wang, K., Gan, T. Y., Li, N., Liu, C. Y., Zhou, L. Y., Gao, J. N., et al. (2017). Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. *Cell Death Differ.* 24, 1111–1120. doi: 10.1038/cdd.2017.61

Wang, L. L., Liu, Y., Yin, C., Asfour, H., Chen, O., Li, Y., et al. (2015). Stoichiometry of Gat4, Mef2c, and Tbx5 influences the efficiency and quality of induced cardiac myocyte reprogramming. *Circ. Res.* 116, 237–244. doi: 10.1161/circresaha.116.305547

Wang, L. L., Liu, Y., Chung, J. J., Wang, T., Gaffey, A. C., Lu, M., et al. (2017). Sustained miRNA delivery from an injectable hydrogel promotes cardiomyocyte proliferation and functional regeneration after ischemic injury. *Nat. Biomed. Eng.* 1, 983–992. doi: 10.1038/s41551-017-0157-y

Wang, Z., Lee, S. J., Cheng, H. J., Yoo, J. J., and Atala, A. (2018). 3D bioprinted functional and contractile cardiac tissue constructs. *Acta Biomater.* 70, 48–56. doi: 10.1016/j.actbio.2018.02.007

Wasala, N. B., Shin, J. H., and Duan, D. (2011). The evolution of heart gene delivery vectors. *J. Gene Med.* 13, 557–565. doi: 10.1002/jgm.1600

Weinberger, F., and Eschenhagen, T. (2021). Cardiac regeneration: new hope for an old dream. *Annu. Rev. Physiol.* 83, 1–23.

Wendel, J. S., Ye, L., Zhang, P., Tranquillo, R. T., and Zhang, J. J. (2014). Functional consequences of a tissue-engineered myocardial patch for cardiac repair in a rat infarct model. *Tissue Eng. Part A* 20, 1325–1335. doi: 10.1089/ten.tea.2013.0312

White, H. D., and Chew, D. P. (2008). Acute myocardial infarction. *Lancet* 372, 570–584.

Wilhelm, M. J. (2015). Long-term outcome following heart transplantation: current perspective. *J. Thorac. Dis.* 7, 549–551.

Wolfraim, J. A., and Donahue, J. K. (2013). Gene therapy to treat cardiovascular disease. *J. Am. Heart Assoc.* 2, e000119.

World Health Organization (2021). Global Action Plan for the Prevention and Control of NCDs 2013-2020. Geneva: World Health Organization.

Wu, P., Chen, H., Jin, R., Weng, T., Ho, J. K., You, C., et al. (2018). Non-viral gene delivery systems for tissue repair and regeneration. *J. Transl. Med.* 16:29.

Xin, M., Olson, E., and Bassel-Duby, R. (2013). Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. *Nat. Rev. Mol. Cell Biol.* 14, 529–541. doi: 10.1038/nrm3619

Yang, S. Y., O’Cearbhaill, E. D., Sisk, G. C., Park, K. M., Cho, W. K., Villiger, M., et al. (2013). A bio-inspired swellable microneedle adhesive for mechanical interlocking with tissue. *Nat. Commun.* 4, 2–11.

Yoo, S. Y., Jeong, S.-N., Kang, J.-I., and Lee, S.-W. (2018). Chimeric adeno-associated virus-mediated cardiovascular reprogramming for ischemic heart disease. *ACS Omega* 3, 5918–5925. doi: 10.1021/acsomega.8b00904

Zhang, Y., Desai, A., Yang, S. Y., Bae, K. B., Antczak, M. I., Fink, S. P., et al. (2015). Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. *Science* 348:aaa2340. doi: 10.1126/science.aaa2340

Zhou, Y., Wang, L., Vaseghi, H. R., Liu, Z., Lu, R., Alimohamadi, S., et al. (2016). BM1 is a key epigenetic barrier to direct cardiac reprogramming. *Cell Stem Cell.* 18, 382–395. doi: 10.1016/j.stem.2016.02.003

Zhu, D., and Cheng, K. (2021). Cardiac cell therapy for heart repair: should the cells be left out? *Cells* 10:641. doi: 10.3390/cells10030641

Zhu, D., Li, Z., Huang, K., Caranasos, T. G., Rossi, J. S., and Cheng, K. (2021). Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair. *Nat. Commun.* 12:1412.

Zhu, W., Zhao, M.,Mattapally, S. C., and Zhang, J. (2018). CCND2 overexpression enhances the regenerative potency of human induced pluripotent stem cell-derived cardiomyocytes: remuscularization of injured ventricle. *Circ. Res.* 122, 88–96. doi: 10.1161/circressaha.117.315104

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chingale, Zhu, Cheng and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.